Integrated clinical and single-cell profiling of BCMA CAR-T therapy in relapsed/refractory multiple myeloma
Locally produced BCMA CAR-T is safe and effective in heavily pretreated R/R MM, inducing deep responses. scRNA-seq/TCR-seq findings highlight interplay of CAR-T heterogeneity, clonal adaptability, and immune regulation. CD8⁺ subset specialization and clonal persistence matter for durable responses; exhaustion and immunosuppression may cause relapse.
Authors
- Jingqiao Qiao (ORCID: https://orcid.org/0009-0000-1877-0044)
- Yiran Wang (ORCID: https://orcid.org/0009-0009-5190-5145)
- Jun-Hui Mei (ORCID: https://orcid.org/0000-0003-0940-5808)
- Ziren Chen
- Xiangyu Meng
- Tang Xiao (ORCID: https://orcid.org/0000-0001-9007-8749)
- Lixin Wang (ORCID: https://orcid.org/0000-0002-5402-8557)
- Hongxin Wang
- Weiqiang Zhao
- Yuanyuan Xu (ORCID: https://orcid.org/0000-0001-8335-5867)
- Li Yu (ORCID: https://orcid.org/0000-0001-6872-2665)
- Wenfa Huang (ORCID: https://orcid.org/0000-0002-9134-3134)
- Chuling Fang (ORCID: https://orcid.org/0000-0002-8381-1823)
- Shuhong Wang (ORCID: https://orcid.org/0000-0001-7624-478X)
- Ziqian He (ORCID: https://orcid.org/0000-0003-4127-2937)
- Lei Wang (ORCID: https://orcid.org/0009-0000-7258-2714)
- Lijun Wang (ORCID: https://orcid.org/0000-0003-3990-6902)
- Yisheng Li
- Chuan Yu
- Guo Xiao
Institutions
- BGI Group (China) (CN)
- Shenzhen University (CN)
- City University of Hong Kong, Shenzhen Research Institute (CN)
- Beike Biotechnology (China) (CN)
- Shenzhen University Health Science Center (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-11-10
- DOI
- https://doi.org/10.1186/s12967-025-07106-w
- Citations
- 1
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China
- Shenzhen University
- Sanming Project of Medicine in Shenzhen
- Shenzhen Key Laboratory Fund